CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫治疗的实践要点：第 20 届国际骨髓瘤学会（IMS）年会报告
英文原题：Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
查看英文原题
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫治疗策略，特别是T细胞重定向疗法，已改变多发性骨髓瘤（MM）的治疗格局。随着两种CAR-T 细胞药物产品和三种复发/难治性MM（RRMM）双特异性抗体/T细胞衔接器（BsAb/TCE）获批，第20届国际骨髓瘤学会（IMS）年会专门安排了一场讨论这些疗法实际应用的专题会议。本文概述该专题讨论内容，包括CAR-T 和BsAb治疗在初诊MM中的作用、急性毒性管理、感染预防和管理，以及T细胞重定向疗法的治疗顺序。
展开英文摘要原文
Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies.
Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies.
论文信息
- 作者
- Raje NS、Cohen AD、Patel KK、van de Donk NWCJ、Richter J、San-Miguel J
- 单位
- Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA. Electronic address: nraje@partners.org.United States
- 文献类型
- 综述
- 期刊
- Clinical lymphoma, myeloma & leukemia2024 Jun
- 原文标识
- PubMed 38627181 · DOI 10.1016/j.clml.2024.03.005